U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Download in electronic PDF format for $75
Abstract: The reasons for which pharmaceutical compounding is the focus of intense state and federal scrutiny are now well known. Compounders are faced with an ever-increasing need to prove, by objective standards, the safety, purity, and potency of the formulations they dispense. They must also demonstrate their compliance with regulations often based on current good compounding practices designed for the pharmaceutical industry. In the U.S. today, rigorous unannounced state and federal inspections of compounding facilities are occurring more and more frequently. To achieve a successful outcome, communicating clearly and effectively with inspectors and having ready access to the information they request are as critical as proving compliance. This article describes the author’s experience with an unannounced United States Food and Drug Administration inspection of his 503A compounding facility and his response to the findings. Readers will learn what to expect during such an inspection, how to prepare for that event, and how to achieve an excellent outcome. Those who would like more information about any of the topics presented are invited to contact the author at the address provided at the close of this article.
Related Keywords:
U.S. Food and Drug Administration, FDA, pharmacy inspection, 503A sterile compounding pharmacies, pharmacy standards, pharmacy regulation, inspectors, documentation, recordkeeping, standard operating procedure, gap analysis
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Yoch Doug
|
Mar/Apr 2017
Pg. 95-102
|
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
|
Jul/Aug 2016
Pg. 351
View Sample |
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
|
Sep/Oct 2017
Pg. 356
|
Certification, Accreditation, and Credentialing for 503A Compounding Pharmacies
Pritchett Jon, McCrory Gary, Kraemer Cheri, Jensen Brenda, Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 7-16
|
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
|
Jan/Feb 2019
Pg. 32-33
|
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
|
Nov/Dec 2015
Pg. 487-488
|
PreScription: Compounding Pharmacy Issues for 2017
Allen Loyd V Jr
|
Jan/Feb 2017
Pg. 4
|
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
|
Jul/Aug 2015
Pg. 303-305
|
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
|
Jul/Aug 2020
Pg. 296-297
|
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration
Kupiec Tom, Kemp Jesse
|
Jul/Aug 2007
Pg. 326-327
|
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Allen Loyd V Jr
|
Sep/Oct 2015
Pg. 389-390
|
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Miller David G
|
May/Jun 2014
Pg. 208
|
Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1
Martin Matt
|
Sep/Oct 2018
Pg. 401-404
|
Applying Quality of Design Concepts to Pharmacy Compounding
Timko Robert J
|
Nov/Dec 2015
Pg. 453-463
|
Compounding Pharmacies: Before and After an Inspection
Kulkarni Darshan, Ricketts Samantha
|
Sep/Oct 2013
Pg. 358-362
|
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Blankenship Cynthia E
|
Sep/Oct 2014
Pg. 379-380
|
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)
|
Nov/Dec 2016
Pg. 457-458
|
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Brunner Scott
|
Jan/Feb 2023
Pg. 22-23
|
Art of Pharmacy v. State
Standridge Rob
|
May/Jun 2022
Pg. 182-186
|
Sterile Basics of Compounding: How to Implement a Robust Visual-inspection Program
Summers Amy
|
Jul/Aug 2022
Pg. 309-315
|
Return to Top |